After scientific quality review and technical evaluation, our journal Exploration of Targeted Anti-tumor Therapy (ETAT) has been officially accepted for PubMed Central (PMC) on 17 August! We are thrilled that this pivotal moment has reached after only two years since launched. All articles since its inception in 2020 will be accessible as soon as article uploading is completed.

The PMC archive of biomedical and life sciences journal literature is a valuable and respected resource provide through the courtesy of US National Institutes of Health's National Library of Medicine. The content of PMC is fully searchable via the PubMed search engine. Access to articles indexed in PMC is free to scholars throughout the world. While ETAT is already indexed in DOAJ and Scopus, achieving a list in PMC matches our priority to give authors maximum visibility.  In the meantime, ETAT will continue to maintain its Free Publication policy, keeping to improve the publication quality.

ETAT appreciates the enthusiastic support and dedicated work by its editorial board members, guest editors, reviewers, authors and readers. The team has worked hard to ensure that papers already published in ETAT represent high quality research in the field of cancer research, and strives to achieve even higher standards in the future so as to become a leading journal in the domain of cancer research.

Latest progress on September 1, 2022:

All ETAT articles since its inception are accessible on PMC: https://www.ncbi.nlm.nih.gov/pmc/journals/4277/